.Pharmacolibrary.Drugs.ATC.M.M05BA08

Information

Zoledronic acid is a third-generation bisphosphonate used primarily for the treatment of osteoporosis, Paget’s disease of bone, and to prevent skeletal-related events in patients with cancers such as multiple myeloma and bone metastases from solid tumors. It is approved and widely used clinically for these indications.

Pharmacokinetics

Pharmacokinetic parameters derived from adult cancer patients (solid tumors, multiple myeloma) receiving single intravenous doses.

References

1. Miller, PD (2011). The kidney and bisphosphonates. Bone 49(1) 77–81. DOI:10.1016/j.bone.2010.12.024 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21232648

2. Shiraki, M, et al., & Nakamura, T (2017). Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis. Journal of bone and mineral metabolism 35(6) 675–684. DOI:10.1007/s00774-016-0806-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28000034

3. Lyseng-Williamson, KA (2008). Zoledronic acid: a review of its use in breast cancer. Drugs 68(18) 2661–2682. DOI:10.2165/0003495-200868180-00010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19093706

Revisions

• 06/2025 initial generated model